Aleva Neuro DBS Europe Light

Personalise patient’s therapy with Directional Deep Brain Stimulation (DBS)

Using the directional Aleva lead with 24 contacts and a Multiple Independent Current Control (MICC) generator, the system delivers the highest precision in directional stimulation allowing physicians to:
  • Improve Therapeutic benefits
  • Minimise side effects
  • Decrease the number of non-responding patients
  • Reduce revisions
Explore Benefits
Aleva Neuro DBS Lausanne Switzerland

Aleva: FROM R&D EXPERTS TO A SOLID COMPANY.

Aleva Neurotherapeutics started as a spin-off of the Swiss Federal Institute of Technology in Lausanne, Switzerland, with the objective of improving the existing Deep Brain Stimulation treatment for patients suffering from Neurological Disorders.

We believed we could do this by improving manufacturing methods, utilising more sophisticated technologies, and with a better focus on the daily needs of Neurologists and Neurosurgeons.

Today, Aleva is a commercial stage company that following directSTIM™’s CE marking, has started its journey by partnering with the leading neurological clinics in Europe, aiming to penetrate the most relevant worldwide markets in the near future.

WE PIONEERED DIRECTIONAL MODE OF DBS

We are the company that pioneered Directional Deep Brain Stimulation in Neuromodulation treatments and our clinically proven technology has set the industry standard for directional leads.1

Aleva’s expertise in Deep Brain Stimulation (DBS) technologies for neurological and psychiatric diseases is demonstrated by 13 patent families and 90 granted patents in this area.

We aim to develop technologies to provide Patients, Neurologists and Neurosurgeons worldwide with a DBS solution that eliminates surgical failures and non-responder patients.

Directional DBS Aleva Neuro
Neurology Deep Brain Images

CLOSE TO OUR CUSTOMERS

We understand the benefits of the DBS technologies and the challenges Neurologists and Neurosurgeons face daily to improve Parkinson’s patients’ lives.

We are aware that if we want to help them overcome these challenges, we need to combine specialisation and the commitment to be responsive to the everyday new challenges experienced by healthcare professionals. This is the attitude you will find in every Aleva employee and sales representative who will be in contact with you.

PROUDLY MADE IN SWITZERLAND

Switzerland has developed highly industrialized precision clusters over the years and now holds a leading position in the field of advanced production processes. Largely a result of its precision watch industry, the country now boasts MEMS and precision manufacturing clusters for Medtech.

Aleva’s headquarters and manufacturing facilities are located in Lausanne, Switzerland near the Swiss Federal Institute of Technology. The directSTIM™ system is fully manufactured and assembled in Switzerland following the highest quality standards and with a precision technology that could be successfully implemented only here.

Aleva Neuro DBS Europe
DBS Visionary Product

A VISIONARY PROJECT SUSTAINED BY SOLID FOUNDATIONS

Our DNA is based on disruptive innovation, and we are committed to continue to develop technologies well ahead of the curve. We are aiming to transform DBS therapy, combining leading technologies and shared data to improve healthcare professional surgical experience and patients’ outcomes.

Our Vision is backed by a new group of investors that will sustain the completion of a journey that started with the introduction of Directional Leads. A reinforced executive team is complementing the existing successful group to partner with Neurosurgeons and Neurologists in the effective deployment of our Vision.

Footnotes

1 Claudio Pollo,  Alain Kaelin-Lang,  Markus F. Oertel,  Lennart Stieglitz,  Ethan Taub, Peter Fuhr,  Andres M. Lozano,  Andreas Raabe,  Michael Schüpbach; Directional deep brain stimulation: an intraoperative double-blind pilot study; Brain, Volume 137, Issue 7, July 2014, Pages 2015–2026.

© 2022 All rights reserved

Website Design & Development by CommuniD

Aleva Neurotherapeutics